Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women

Journal of Bone and Mineral Metabolism

Volumn 33, Issue 1, 2015, Pages 93-100

  Nagase, Shinichi ^a   Ohyama, Michiyo ^a   Hashimoto, Yoshitaka ^a   Small, Maria ^a   Sharpe, John ^a   Manako, Junichiro ^a   Kuwayama, Tomohiro ^a   Deacon, Steve ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Cathepsin K inhibitor; CTX I; ONO 5334; Osteoporosis; Sustained release formulation

Indexed keywords

ALENDRONIC ACID; CATHEPSIN K; COLLAGEN TYPE 1; DELAYED RELEASE FORMULATION; ONO-5334; THIAZOLIDINE DERIVATIVE;

AGED; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; BONE; BONE DENSITY; CHEMISTRY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELAYED RELEASE FORMULATION; DRUG EFFECTS; FEMALE; HUMAN; MIDDLE AGED; OSTEOLYSIS; OSTEOPOROSIS; PHARMACOKINETICS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; URINE;

AGED; ALENDRONATE; AREA UNDER CURVE; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CATHEPSIN K; COLLAGEN TYPE I; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; SINGLE-BLIND METHOD; THIAZOLIDINES;

EID: 84892771725     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-013-0558-2     Document Type: Article

References (17)

1. Berti PJ, Storer AC (1995) Alignment/phylogeny of the papain superfamily of cysteine proteases. J Mol Biol 246:273–283
2. Nishi Y, Atley L, Eyre DE, Edelson JG, Superti-Furga A, Yasuda T, Desnick RJ, Gelb BD (1999) Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res 14:1902–1908
3. Gelb BD, Shi GP, Chapman HA, Desnick RJ (1996) Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236–1238
4. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K (1998) Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 95:13453–13458
5. Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, Bertoncello I, Drake F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I (1999) Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14:1654–1663
6. Data on File. Inhibitory effect of ONO-5334 on human recombinant cathepsin K (E05QA012). Ono Pharmaceutical Co., Ltd.
7. Data on File. Inhibitory effect of ONO-5334 on 6 cystein proteases (E05QA025). Ono Pharmaceutical Co., Ltd.
8. Data on File. An Investigation of Ono’s Compound (ONO-5334) on 9 Enzyme and 3 Receptor Binding Assays (1056356). Ono Pharmaceutical Co., Ltd.
9. Yamada H, Mori H, Nakanishi Y, Kunishige A, Nishikawa S, Tanaka M, Shiroya (2009) Orally active cathepsin K inhibitor, ONO-5334, potently improved bone mineral density not only in trabecular bone but also in cortical bone in ovariectomized cynomolgus monkeys. Presented at American Society for Bone and Mineral Research, abstract A09002146.
10. Nagase S, Ohyama M, Hashimoto Y, Small M, Kuwayama T, Deacon S (2012) Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple dose Phase I study. J Clin Pharm 52:306–318
11. Eastell R, Nagase S, Ohyama M, Small M, Sawyer J, Boonen S, Spector T, Kuwayama T, Deacon S (2011) Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J Bone Miner Res 26:1303–1312
12. Eastell R, Nagase S, Small M, Boonen S, Spector T, Ohyama M, Kuwayama T, Deacon S (2013) Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. J Bone Miner Res. doi:10.1002/jbmr.2047
13. Engelke K, Nagase S, Fuerst T, Eastell R, Genant H, Small M, Kuwayama T, and Deacon S (2012) Effects of the cathepsin K inhibitor, ONO-5334, on BMD as measured by 3D QCT in the hip and the spine after 2 years of treatment. Presented at IOF-ECCEO12 European Congress on Osteoporosis and Osteoarthritis, Bordeaux, France
14. Ochi Y, Yamada H, Mori H, Nakanishi Y, Nishikawa S, Kayasuga R, Kawada N, Kunishige A, Hashimoto Y, Tanaka M, Sugitani M, Kawabata K (2011) Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism. Bone 49:1351–1356
15. Bjarnason NH, Henriksen EEG, Alexandersen P, Christgau S, Henriksen DB, Christiansen C (2002) Mechanism of circadian variation in bone resorption. Bone 30:307–313
16. Schlemmer A, Hassager C, Jensen SB, Christiansen C (1992) Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 74:476–480
17. Small M, Dijk D-J, Eastell R, Greenwood A, Sharpe J, Yuba M, Yamada H, Deacon S (2012) Quantification of the circadian modulation of the bone resorption marker CTX-I in serum and urine under controlled in-patient conditions. J Bone Miner Res 27(Suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/Abstracts12.aspx. Accessed 9 Sept 2013